Astec Lifesciences Ltd Share Price – NSE /  BSE

Agro Chemicals, Small Cap

Astec Lifesciences announced that the 31th Annual General Meeting(AGM) of the company will be held on 28 July 2025.

Powered by Capital Market - Live News

Revenue from operations declined 22.26% YoY to Rs 119.53 crore in the quarter ended 31 March 2025.

Loss before tax stood at Rs 15.66 crore in Q4 FY25, widening from a loss of Rs 0.93 crore in the same period last year.

EBITDA came in at Rs 6.32 crore in Q4 FY25, down 57.18% from Rs 14.76 crore reported in Q4 FY24.

Total expense tanked 13.23% year on year to Rs 135.98 crore during the quarter. The cost of materials consumed was Rs 85.45 crore (up 3.58% YoY), while employee benefits expense stood at Rs 14.43 crore (down 1.77% YoY) during the period under review.

On the margins front, operating margin narrowed to 4.62% in Q4 FY25, compared to 8.27% in Q4 FY24.

N. B. Godrej, chairman of Astec LifeSciences, said, ?In Q4 FY25, Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to an increase in volumes and prices in the enterprise business coupled with an improved product mix in the CDMO business. We expect an uptick in the demand for enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.?

Astec Lifesciences is into the manufacturing of agrochemical active ingredients (technical), bulk and formulations, and intermediate products, and it sells its products in India as well as exports them to approximately 24 countries.

Powered by Capital Market - Live News

Net Loss of Astec Lifesciences reported to Rs 16.09 crore in the quarter ended March 2025 as against net loss of Rs 0.97 crore during the previous quarter ended March 2024. Sales declined 22.26% to Rs 119.53 crore in the quarter ended March 2025 as against Rs 153.75 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 134.75 crore in the year ended March 2025 as against net loss of Rs 46.93 crore during the previous year ended March 2024. Sales declined 16.78% to Rs 381.30 crore in the year ended March 2025 as against Rs 458.18 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Revenue from operations declined 22.26% YoY to Rs 119.53 crore in the quarter ended 31 March 2025.

Loss before tax stood at Rs 15.66 crore in Q4 FY25, widening from a loss of Rs 0.93 crore in the same period last year.

EBITDA came in at Rs 6.32 crore in Q4 FY25, down 57.18% from Rs 14.76 crore reported in Q4 FY24.

Total expense tanked 13.23% year on year to Rs 135.98 crore during the quarter. The cost of materials consumed was Rs 85.45 crore (up 3.58% YoY), while employee benefits expense stood at Rs 14.43 crore (down 1.77% YoY) during the period under review.

On the margins front, operating margin narrowed to 4.62% in Q4 FY25, compared to 8.27% in Q4 FY24.

N. B. Godrej, chairman of Astec LifeSciences, said, ?In Q4 FY25, Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to an increase in volumes and prices in the enterprise business coupled with an improved product mix in the CDMO business. We expect an uptick in the demand for enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.?

Astec Lifesciences is into the manufacturing of agrochemical active ingredients (technical), bulk and formulations, and intermediate products, and it sells its products in India as well as exports them to approximately 24 countries.

Powered by Capital Market - Live News

Net Loss of Astec Lifesciences reported to Rs 16.09 crore in the quarter ended March 2025 as against net loss of Rs 0.97 crore during the previous quarter ended March 2024. Sales declined 22.26% to Rs 119.53 crore in the quarter ended March 2025 as against Rs 153.75 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 134.75 crore in the year ended March 2025 as against net loss of Rs 46.93 crore during the previous year ended March 2024. Sales declined 16.78% to Rs 381.30 crore in the year ended March 2025 as against Rs 458.18 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 23 April 2025.

Powered by Capital Market - Live News

Astec Lifesciences announced that the 31th Annual General Meeting(AGM) of the company will be held on 28 July 2025.

Powered by Capital Market - Live News

Revenue from operations declined 22.26% YoY to Rs 119.53 crore in the quarter ended 31 March 2025.

Loss before tax stood at Rs 15.66 crore in Q4 FY25, widening from a loss of Rs 0.93 crore in the same period last year.

EBITDA came in at Rs 6.32 crore in Q4 FY25, down 57.18% from Rs 14.76 crore reported in Q4 FY24.

Total expense tanked 13.23% year on year to Rs 135.98 crore during the quarter. The cost of materials consumed was Rs 85.45 crore (up 3.58% YoY), while employee benefits expense stood at Rs 14.43 crore (down 1.77% YoY) during the period under review.

On the margins front, operating margin narrowed to 4.62% in Q4 FY25, compared to 8.27% in Q4 FY24.

N. B. Godrej, chairman of Astec LifeSciences, said, ?In Q4 FY25, Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to an increase in volumes and prices in the enterprise business coupled with an improved product mix in the CDMO business. We expect an uptick in the demand for enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.?

Astec Lifesciences is into the manufacturing of agrochemical active ingredients (technical), bulk and formulations, and intermediate products, and it sells its products in India as well as exports them to approximately 24 countries.

Powered by Capital Market - Live News

Net Loss of Astec Lifesciences reported to Rs 16.09 crore in the quarter ended March 2025 as against net loss of Rs 0.97 crore during the previous quarter ended March 2024. Sales declined 22.26% to Rs 119.53 crore in the quarter ended March 2025 as against Rs 153.75 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 134.75 crore in the year ended March 2025 as against net loss of Rs 46.93 crore during the previous year ended March 2024. Sales declined 16.78% to Rs 381.30 crore in the year ended March 2025 as against Rs 458.18 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Revenue from operations declined 22.26% YoY to Rs 119.53 crore in the quarter ended 31 March 2025.

Loss before tax stood at Rs 15.66 crore in Q4 FY25, widening from a loss of Rs 0.93 crore in the same period last year.

EBITDA came in at Rs 6.32 crore in Q4 FY25, down 57.18% from Rs 14.76 crore reported in Q4 FY24.

Total expense tanked 13.23% year on year to Rs 135.98 crore during the quarter. The cost of materials consumed was Rs 85.45 crore (up 3.58% YoY), while employee benefits expense stood at Rs 14.43 crore (down 1.77% YoY) during the period under review.

On the margins front, operating margin narrowed to 4.62% in Q4 FY25, compared to 8.27% in Q4 FY24.

N. B. Godrej, chairman of Astec LifeSciences, said, ?In Q4 FY25, Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to an increase in volumes and prices in the enterprise business coupled with an improved product mix in the CDMO business. We expect an uptick in the demand for enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.?

Astec Lifesciences is into the manufacturing of agrochemical active ingredients (technical), bulk and formulations, and intermediate products, and it sells its products in India as well as exports them to approximately 24 countries.

Powered by Capital Market - Live News

Net Loss of Astec Lifesciences reported to Rs 16.09 crore in the quarter ended March 2025 as against net loss of Rs 0.97 crore during the previous quarter ended March 2024. Sales declined 22.26% to Rs 119.53 crore in the quarter ended March 2025 as against Rs 153.75 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 134.75 crore in the year ended March 2025 as against net loss of Rs 46.93 crore during the previous year ended March 2024. Sales declined 16.78% to Rs 381.30 crore in the year ended March 2025 as against Rs 458.18 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 23 April 2025.

Powered by Capital Market - Live News